<prompt> Amphotericin B toxicity can be reduced by?Incorporating it in liposomal complexCombining with fluconazoleCombining with flucytosineInjecting the drug with dextrose  <response>: New amphotericin B formulations: In an attempt to improve tolerability of i.v. infusion of AMB, reduce its toxicity and achieve targeted delivery, 3 new lipid formulations of AMB have been produced. a Amphotericin B lipid complex ABLC: Contains 35 AMB incorporated in ribbon like paicles of dimyristoyl phospholipids. b Amphotericin B colloidal dispersion ABCD. Disc shaped paicles containing 50 each of AMB and cholesteryl sulfate are prepared as aqueous dispersion c Lpi osomal amphotericin B small unilamellar vesicles SUV: Consists of 10 AMB incorporated in uniform sized 60-80 nM unilamellar liposomes made up of lecithin and other biodegradable phospholipids. The special features of these preparations are: They, except ABCD, produce milder acute reaction especially liposomal formulation on i.v. infusion. They can be used in patients not tolerating infusion oi conventional AMB formulation. They have lower nephrotoxicity. They cause minimal anaemia. The liposomal preparation delivers AMB paicularh to reticuloendothelial cells in liver and spleen---especialh valuable for kala azar and in immunocompromised patients ESSENTIALS OF MEDICAL PHARMACOLOGY K.D.TRIPATHI SIXTH EDITION PAGE NO:758 